Compare GSK Pharma with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA PROCTER & GAMBLE HEALTH GSK PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 32.3 53.9 60.0% View Chart
P/BV x 12.9 4.7 274.5% View Chart
Dividend Yield % 1.2 10.1 12.2%  

Financials

 GSK PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
GSK PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs3,5953,549 101.3%   
Low Rs1,2531,301 96.3%   
Sales per share (Unadj.) Rs184.7511.4 36.1%  
Earnings per share (Unadj.) Rs26.361.3 42.9%  
Cash flow per share (Unadj.) Rs29.274.0 39.4%  
Dividends per share (Unadj.) Rs20.00440.00 4.5%  
Dividend yield (eoy) %0.818.1 4.5%  
Book value per share (Unadj.) Rs126.3927.8 13.6%  
Shares outstanding (eoy) m169.4016.60 1,020.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.14.7 276.8%   
Avg P/E ratio x92.239.6 233.0%  
P/CF ratio (eoy) x83.132.8 253.7%  
Price / Book Value ratio x19.22.6 734.1%  
Dividend payout %76.1717.9 10.6%   
Avg Mkt Cap Rs m410,62640,257 1,020.0%   
No. of employees `0005.01.1 437.4%   
Total wages/salary Rs m5,3721,313 409.2%   
Avg. sales/employee Rs Th6,306.77,486.7 84.2%   
Avg. wages/employee Rs Th1,083.11,157.6 93.6%   
Avg. net profit/employee Rs Th898.0897.2 100.1%   
INCOME DATA
Net Sales Rs m31,2818,490 368.5%  
Other income Rs m1,023244 419.5%   
Total revenues Rs m32,3048,734 369.9%   
Gross profit Rs m6,0091,482 405.6%  
Depreciation Rs m486211 230.1%   
Interest Rs m60-   
Profit before tax Rs m6,5401,514 431.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m28766 437.5%   
Tax Rs m2,373563 421.9%   
Profit after tax Rs m4,4541,017 437.8%  
Gross profit margin %19.217.5 110.1%  
Effective tax rate %36.337.1 97.7%   
Net profit margin %14.212.0 118.8%  
BALANCE SHEET DATA
Current assets Rs m20,06115,343 130.8%   
Current liabilities Rs m14,5431,960 741.9%   
Net working cap to sales %17.6157.6 11.2%  
Current ratio x1.47.8 17.6%  
Inventory Days Days5749 116.5%  
Debtors Days Days1428 49.4%  
Net fixed assets Rs m14,3431,209 1,186.0%   
Share capital Rs m1,694166 1,020.5%   
"Free" reserves Rs m19,70415,235 129.3%   
Net worth Rs m21,39815,401 138.9%   
Long term debt Rs m20-   
Total assets Rs m39,11317,595 222.3%  
Interest coverage x1,091.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.80.5 165.7%   
Return on assets %11.45.8 197.2%  
Return on equity %20.86.6 315.1%  
Return on capital %31.910.3 311.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5341,636 32.6%   
Fx outflow Rs m7,0914,368 162.3%   
Net fx Rs m-6,557-2,732 240.0%   
CASH FLOW
From Operations Rs m3,994-1,304 -306.3%  
From Investments Rs m-1,43312,697 -11.3%  
From Financial Activity Rs m-3,584-301 1,192.5%  
Net Cashflow Rs m-1,02311,093 -9.2%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 51.8 97.9%  
Indian inst/Mut Fund % 10.2 18.2 56.0%  
FIIs % 23.8 1.0 2,380.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 29.1 52.9%  
Shareholders   102,036 28,591 356.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   WYETH LTD  IPCA LABS  NATCO PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Lower, India's October Exports, and Top Cues in Focus Today(Pre-Open)

India share markets ended their day marginally lower yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 72 points (down 0.2%).

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 18, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS